New products, merger to drive Glaxo - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

New products, merger to drive Glaxo

Aug 2, 2000

Glaxo seems to be a new high these days. The proposed merger with SmithKline is likely to come through sooner than expected. The company has reported very healthy results for the second quarter with a topline growth of over 27%, when the overall pharmaceutical industry is growing by not more than 10% per annum. Most important, Glaxo’s parent seems willing to introduce new products through the listed company. What however seems to be driving the company’s stock seems to be the sooner–than–expected merger with SmithKline.

The merged company with a market share of 7% will be way ahead of competitors Cipla and Ranbaxy. It will have brands such as Iodex, Augmentin (an amoxycillin–clavulanic acid combination), Engerix (Hepatitis B vaccine), Zevit and Livogen (vitamins and minerals), which will complement its prescription led product profile. Glaxo, at present, has a presence in a large number of therapy areas (over 60% of the market). It is a market leader in 80% of the segments in which the company operates and has a large portfolio of over 200 product packs. Besides, the company enjoys the trust of the medical profession. Its prescription brands such as Betnovate (dermatologicals), Zinetac (ranitidine), Becadexamin (vitamin) Cetzine (anti–histamine) are as well known as over the counter products in their own right. The company has a clean balance sheet and a first class management. Besides, the merged entity will also command an enviable marketing network that will go a long way in its attempt to increase market share.

SmithKline Consumer has a presence in health food drinks through the brands ‘Horlicks’, ‘Viva’ and ‘Maltova’. Glaxo, on the other hand, has sold its brand ‘Farex’ which operated in a similar space a few year’s back. Since the parent’s operations are likely to be restricted to pharmaceuticals it is quite possible that the merged company in India could disinvest the healthfood operations. Another side effect of the impending merger is that Glaxo is likely to inherit SmithKline’s 100% subsidiary in India i.e. SmithKline Beecham Asia. Whether ‘Crocin’ ‘Tums’ and ‘Eno’ continue to remain a part of the parent’s 100% subsidiary will demonstrate the parent’s attitude towards the minority shareholders.

As far as new products are concerned the company has lined up a slew of new launches over the next 12–18 months. Overall the company would continue to focus on the therapy areas of the future such as respiratory, anti–virals, osteoporosis and consolidate in dermatologicals, gastrointestinals and antibiotics.

Glaxo's new products
Brand Purpose Introduced
Hepitec Hepatitis–B Yes
Seretide Asthma Yes
Lamictal Epilepsy No
Valtrex Viral Infections No
Epivir AIDS Yes
Combivir AIDS Yes
Zoderm Oxiconazole No
Histofreezer Wart removal Yes

Glaxo has posted a mixed performance over the last two year’s. However, the pending mergers with Burroughs Wellcome and SmithKline Beecham and its recent attempts to restructure its operations have the potential to rev up its performance in the coming year’s.

Equitymaster requests your view! Post a comment on "New products, merger to drive Glaxo". Click here!

  

More Views on News

GSK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of GSK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Dec 3, 2021 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS